公开(公告)号：US20250011307A1

公开(公告)日：2025-01-09

申请号：US18687609

申请日：2022-08-30

Applicant: Novartis AG

Inventor： Runyan LI ,  Bo LIU ,  Michael MUTZ ,  Lina YUAN ,  Yingcong ZHOU

IPC: C07D405/04 ,  A61K31/343 ,  A61K31/4025 ,  C07D307/81

Abstract: The present invention generally relates to crystalline polymorphic forms of the biaryl YAP/TAZ-TEAD protein-protein interaction inhibitors 4-((2S,4S)-5-Chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide and 2-((2S,3S,4S)-5-Chloro-6-fluoro-3-methyl-2-((methylamino)methyl)-2-phenyl-2,3-dihydrobenzofuran-4-yl)-3-fluoro-4-methoxybenzamide and salts thereof, as well as methods of using the forms in the treatment of cancer.